ArticleClinical drug investigation2025
Radioligand Therapies (RLTs) and Healthcare System Readiness: From the Experience in GEP-NET, a Retrospective Analysis on DRG and Mobility to Improve the Accessibility to the Future RLT in Italy.
Article in Clinical drug investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesGastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare diverse group of malignancies, which range from well-differentiated indolent tumors to high-grade aggressive forms. Based on the World Health Organization classification, GEP-NETs are divided into well-differentiated neuroendocrine tumors and poorly differentiated carcinomas. While localized GEP-NETs are primarily treated surgically, non-resectable GEP-NETs have evolved toward targeted therapies, including radioligand therapy. This study describes inpatient resource utilization and inter-regional healthcare mobility for patients with GEP-NETs in Italy, focusing on radioligand therapy.
methodsWe retrieved Italian Hospital Discharge Records (SDO) from 2018 to 2021. Given the absence of specific International Classification of Diseases, Ninth Revision, Clinical Modification codes for GEP-NETs, all potentially related diagnoses were included. Radioligand therapy-related hospitalizations were identified using Diagnosis-Related Group code 409 for radiotherapy, focusing on discharge disciplines of nuclear medicine, radiotherapy, or radiation oncology. We analyzed hospitalization rates by region and regimen and assessed inter-regional mobility using the Attraction and Escape Mobility Indexes.
resultsOver the study period, 4837 radioligand therapy-related GEP-NET hospitalizations were recorded, with 2942 involving the targeted disciplines. Hospitalizations increased by 48.4%, mainly owing to growth in short-stay (0-1 day) discharges (from 37 in 2018 to 228 in 2021), while longer stays (≥ 2 days) rose from 552 to 644. Day hospital accounted for only 0.2% of cases. Regional disparities were prominent, with Emilia-Romagna, Lombardia, and Sicilia managing 88.9% of cases; ten regions recorded no hospitalizations, reflecting a high mobility index (45.8%) and significant inter-regional patient mobility.
conclusionsThe study underscores the need for regulatory adjustments, resource allocation improvements, and healthcare system adaptations to effectively support innovative therapies for GEP-NETs. Addressing these needs is essential to optimize patient outcomes and address regional disparities in Italy's healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.